Mesenchymal stem cells-bridge catalyst between innate and adaptive immunity in COVID 19.
Adaptive Immunity
Betacoronavirus
COVID-19
Catalysis
Comorbidity
Coronavirus Infections
/ immunology
Cytokine Release Syndrome
/ virology
Cytokines
/ immunology
Humans
Immunity, Innate
Mesenchymal Stem Cell Transplantation
Mesenchymal Stem Cells
/ cytology
Pandemics
Pneumonia, Viral
/ immunology
SARS-CoV-2
Th1 Cells
/ immunology
Treatment Outcome
Journal
Medical hypotheses
ISSN: 1532-2777
Titre abrégé: Med Hypotheses
Pays: United States
ID NLM: 7505668
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
received:
21
04
2020
accepted:
14
05
2020
pubmed:
20
5
2020
medline:
12
9
2020
entrez:
20
5
2020
Statut:
ppublish
Résumé
Majority of patients infected with the COVID 19 virus display a mild to moderate course of disease and spontaneously recover at 14-20 days. However, about 15% of patients progress to severe stages and 2.5% of these patients succumb to this illness. Most patients with severe disease belong to the elderly age group (<65 years of age) and have multiple associated co-morbidities. The immune responses induced by the COVID 19 virus, during the incubation and non-severe stages, requires the early initiation of a specific adaptive immune response to eliminate the virus and prevent the progress to severe stages. In patients with a dysfunctional bridge adaptive immunity, the innate immune response becomes exaggerated due to the lack of feedback from the adaptive immune cells. The resultant cytokine storm is responsible for the severe lung injury leading to acute respiratory distress syndrome seen in COVID 19 patients. Mesenchymal stem cells are known to suppress overactive immune responses as well as bring about tissue regeneration and repair. This immuno-modulatory effect of MSCs could hold potential to manage a patient with severe symptoms of COVID 19 infection due to a dysfunctional adaptive immune system.
Identifiants
pubmed: 32425307
doi: 10.1016/j.mehy.2020.109845
pii: S0306-9877(20)30922-1
pii: 109845
pmc: PMC7232064
pii:
doi:
Substances chimiques
Cytokines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
109845Informations de copyright
© 2020 Published by Elsevier Ltd.
Références
Lancet Respir Med. 2020 Apr;8(4):420-422
pubmed: 32085846
Nat Med. 2020 Apr;26(4):453-455
pubmed: 32284614
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Nat Immunol. 2014 Nov;15(11):1009-16
pubmed: 25329189
Bioinformation. 2020 Mar 31;16(3):219-222
pubmed: 32308263
Am J Hematol. 2020 Jun;95(6):E131-E134
pubmed: 32129508
Nat Rev Microbiol. 2016 Aug;14(8):523-34
pubmed: 27344959
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
EBioMedicine. 2020 May;55:102763
pubmed: 32361250
Lancet. 2020 Mar 28;395(10229):1033-1034
pubmed: 32192578
Lancet Respir Med. 2014 Dec;2(12):1016-26
pubmed: 25465643
Nat Rev Immunol. 2012 Apr 25;12(5):383-96
pubmed: 22531326
Cell Death Differ. 2020 May;27(5):1451-1454
pubmed: 32205856
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
Eur J Cell Biol. 2019 Dec;98(5-8):151041
pubmed: 31023504
Lancet Respir Med. 2015 Jan;3(1):24-32
pubmed: 25529339
Aging Dis. 2020 Mar 9;11(2):216-228
pubmed: 32257537